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Sir Henry Hallet Dale can undisputedly be accoladed as one
of the greatest British pharmacologists of the twentieth cen-
tury. His work was pivotal in laying down the principles of
chemical neurotransmission. This article gives some account
of Dale’s life and his most important discoveries, including
the identiﬁcation of acetylcholine as a neurotransmitter in the
autonomic and somatic nervous systems.
Introduction
The concept of chemical neurotransmission at the synapse is one
of the fundamental keystones on which neuroscience is built. In-
deed, without the knowledge of chemical neurotransmission, it
would be impossible to understand how the nervous system,
including the brain, operates. Sir Henry Dale’s identiﬁcation
of acetylcholine as a neurotransmitter at several sites in the pe-
ripheral nervous system1 1The peripheral nervous sys-
tem is composed of (1) the au-
tonomic nervous system which
has sympathetic and parasym-
pathetic branches, and (2) the
somatic nervous system which
controls the skeletal muscles.
, including the synapse between the pre-
ganglionic and post-ganglionic ﬁbres of the sympathetic system2;
the post-ganglionic parasympathetic synapse; and the neuromus-
cular junction3, were groundbreaking advances in proving that
neurons communicate with each other using chemical messengers4.
In addition, Dale recognised that acetylcholine had both mus-
carinic and nicotinic-like actions depending on its site of action.
Further discoveries made by Dale included the role of histamine,
which he showed was a natural constituent of the body and in- Keywords
Dale, acetylcholine, histamine, re-
ceptors, neurotransmission, auto-
nomic nervous system, somatic
nervous system.
volved in anaphylactic shock; the pituitary hormone oxytocin and
the ﬁrst adrenergic blocking agents now being used to treat a
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range2Both the sympathetic and
parasympathetic systems
are composed of a chain
of two motor neurons. The
preganglionic ﬁbres originate
in the spinal cord and these
synapse onto postganglionic
ﬁbres which provide the ﬁnal
output to the organs of the
body.
of disorders. Perhaps, not surprisingly, these scientiﬁc achieve-
ments tend to overshadow many of Dale’s other contributions to
the development of pharmacology, including his role as a research
director and scientiﬁc politician. Indeed, his inﬂuence is still
strongly felt today – for both his contribution to promoting an in-
ternational pharmacologic standardisation, as well as for coining
a large number of terms that remain in common usage including
‘sympathomimetic’, ‘cholinergic’ and ‘adrenergic’. Dale’s out-
standing deeds were recognised by numerous degrees from more
than twenty universities. In addition, he was a recipient of many
other distinctions, including the presidency3The somatic nervous system
has only one synapse – at the
junction of the motor nerve ﬁ-
bre and muscle (neuromuscular
junction or NMJ).
of the Royal Society,
a knighthood and a Nobel Prize.
Early Life and Studies
Dale was born in London (1875), the third son of seven chil-
dren, into a relatively prosperous4Electrical synapses are also
known to exist but are much
rarer than chemical ones.
middle-class family (his father,
Charles James Dale, was an active Methodist and manager of a
Derbyshire stoneware ﬁrm). After being educated at small public
schools, Dale won a scholarship to the Leys School in Cambridge
in 1891 – an institution strongly focussed on getting its Methodist
students into Cambridge University and its colleges. The school
was also unusual for its promotion of science, and it was here
that Dale would make his ﬁrst forays into biological experimenta-
tion using frog muscle-nerve preparations and simple histological
techniques. After winning a scholarship to enter Trinity College
in 1894 to study natural sciences, Dale came under the inﬂuence
of John Langley55Langley coined the terms ‘au-
tonomic’, ‘sympathetic’, and
‘parasympathetic’. He was also
the ﬁrst, in 1905, to suggest that
many drugs worked on pharma-
cological receptors.
and Walter Gaskell, leading to his ﬁrst scien-
tiﬁc paper in 1900. Leaving Cambridge in the same year to ﬁnish
his medical training in 1904 at St. Bartholomew’s Hospital, Lon-
don, Dale would spend some of his time working at University
College with Ernest Starling and William Bayliss. It was here
that Dale ﬁrst met Otto Loewi, who became a lifelong friend and
co-recipient of the Nobel Prize.
In his semi-autobiographical Adventures in Physiology (1953),
Dale claims he was faced with a bleak academic prospect after
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Figure 1. A photograph of
Henry Dale taken in 1918 at
the Lister Institute for Pre-
ventive Medicine. Source:
Wellcome Library, London.
completing his medical training in 1904, which Dale ﬁrst met Otto
Loewi in 1902 at St
Bartholomew’s Hospital,
London (where a plaque
in the pathology museum
marks the site where
Sherlock Holmes and
Doctor Watson ﬁrst met).
was also the year
of his marriage to his childhood sweetheart and cousin, Ellen Har-
riet Hallet. With the need for ﬁnancial stability in mind, Dale
accepted appointment as a pharmacologist at the newly estab-
lished Wellcome Physiological Research Laboratories in London.
This was an unusual choice since the Wellcome Institute was a
non-proﬁting concern, created by the American, Henry Wellcome
(later Sir) aimed at scientiﬁc advancement for the beneﬁt of all.
In fact, this objective had already been met when Wellcome was
able to produce an economically viable antitoxin for diphtheria
in 1894. It was also an appointment that went against the advice
of his university friends who feared it would compromise Dale’s
independence as a researcher. However, the Wellcome Institute
oﬀered a secure income with the chance of career advancement,
and Dale was to take full advantage of this situation by becoming
its Director in 1906.
When Dale started work in his new job, he was asked to exam-
ine the chemical constituents of a parasitic fungus Claviceps pur-
purea, otherwise known as ergot, which had been known to infect
rye and other cereal grasses in the medieval times. This had led
to epidemic outbreaks called St. Anthony’s ﬁre that was associ-
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ated with convulsions, hallucinations and intense burning sensa-
tions in its victims. Later, in the eighteenth century, ergot was
found to cause constriction of blood vessels and uterus, resulting
in its adoption by midwives, who used it to induce abortions or
stop bleeding after childbirth. Dale admitted he was “not at all
attracted by the prospect” of making his ﬁrst career move into ex-
amining “the ergot morass”. Yet, Wellcome’s suggestionAt ﬁrst Dale was “not at
all attracted by the
prospect” of examining
the chemical properties
of ergot.
turned
out to be a fortuitous one. As Dale began to examine ergot, he
realised it was a treasure trove of active pharmacological sub-
stances, many of which were isolated by his colleague and bril-
liant young chemist George Barger.
Dale’s ﬁrst breakthrough with ergot came by a stroke of good for-
tune. One day he was asked to test an extract from the adrenal
glands to see if it contained adrenaline. He tested the extract by
injecting it into a cat pre-treated with ergot and found that the
animal’s adrenal-induced blood pressure did not increase as ex-
pected. Clearly, there was something in the ergot inhibiting the
eﬀects of the adrenal extract. Indeed, this turned out to be a sub-
stance called ergotoxine, which blocked the constricting eﬀects of
adrenaline on the smooth muscle of blood vessels. Dale had not
only discovered the ﬁrst alpha-adrenergic blocking agents, which
are now used to treat a range of medical conditions66Alpha-adrenergic blocking
agents act to dilate the blood
vessels and are used to lower
blood pressure.
, but he also
realised that receptors for adrenaline must exist on the arterioles
which he called ‘adrenoreceptors’. This discovery also encour-
aged Dale to examine more closely the role of noradrenaline – a
substance then commercially available. Dale soon realised that
noradrenaline mimicked the eﬀects of sympathetic nervous stim-
ulation better than adrenaline itself. Although he did not go as far
as to suggest that noradrenaline was acting as a neurotransmit-
ter in the sympathetic nervous system, this would eventually be
shown to be the case in the 1940s, largelySir Henry Dale was
unique among
biomedical scientists
since he never held a
primary academic post at
a university.
as a result of research
by Ulf von Euler in Sweden.
In 1910, Dale and Barger identiﬁed another chemical in ergot
which caused the uterine smooth muscle and bronchioles to con-
strict. This substance also caused a fall in blood pressure, with
injections into animals producing many symptoms of anaphylac-
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tic shock – a severe and potentially life-threatening response of-
ten triggered by an allergic reaction. In fact, they had discovered
histamine, shown a year later by Dale to be a naturally occurring
chemical in the body, after he isolated it from the walls of the
intestine. Over the next decade, Dale would show that histamine
is distributed throughout the body and is released by biological
tissues in response to injury, where it supported the immune re-
sponse by allowing capillary dilation and ‘leakage’. This discov-
ery was of great importance in surgery, especially during World
War 1, when the control of anaphylactic shock was necessary to
avoid serious and fatal complications. Later, in the 1940s, his-
tamine was also found in the brain’s nervous tissue and identiﬁed
as a neurotransmitter in the 1960s.
The Discovery of Acetylcholine
Undoubtedly, Dale’s most important Undoubtedly, Dale’s
most important
discovery was
establishing the role of
acetylcholine in
autonomic and somatic
nervous function.
discovery was establishing
the role of acetylcholine in autonomic and somatic nervous func-
tion. This story ﬁrst began in 1913 when Dale was asked to test a
routine extract of ergot. Normally, ergot would have produced a
modest rise in arterial blood pressure when injected into an anaes-
thetized cat – although on this occasion, the extract had the op-
posite eﬀect. At ﬁrst, Dale thought he had inadvertently injected
a life-threatening air bubble into the animal, but with repeated
testing realised this was not the case. Instead, Dale began to
suspect that ergot might contain muscarine. This chemical, ﬁrst
extracted from the iconic red and white spotted ﬂy agaric mush-
room (Amanita muscaria), was of great interest to pharmacolo-
gists since it produced a number of eﬀects including bradycardia,
hypotension and pupil constriction. All of these actions were ones
that closely mimicked the action of the parasympathetic nervous
system. However, after working with colleague Arthur Ewins,
Dale realised that the depressor substance in ergot was actually
acetylcholine. This chemical was already known to physiologists
since choline had been found in the adrenal glands and shown
to reduce blood pressure, an eﬀect that had led Reid Hunt to
synthesise a number of choline derivatives – one of which was
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acetylcholine. Remarkably, this chemical was a hundred thou-
sand times more active than choline in its biological eﬀects, sug-
gesting a pharmacological role. The implication, although Dale
was careful not to endorse it at the time, was that acetylcholine
acted as a neurotransmitter in the parasympathetic system; a con-
troversial idea since few pharmacologists endorsed chemical neu-
rotransmission, and acetylcholine had yet to be found in the body.
AlthoughIn 1914, Dale realised
that the eﬀects of
acetylcholine could be
mimicked by two
diﬀerent types of
substance – muscarine
and nicotine.
muscarine and acetylcholine had similar physiological
eﬀects in many areas of the body, there were notable exceptions.
One was the neuromuscular junction where only acetylcholine
caused muscle contraction. This site also showed another inter-
esting characteristic since the eﬀects of acetylcholine were mim-
icked here by nicotine. Moreover, both acetylcholine and nicotine
were blocked by curare. In contrast, the action of muscarine on
the parasympathetic system was blocked by the alkaloid atropine.
Dale oﬀered an explanation for these results in 1914 when he pro-
posed the existence of two types of cholinergic receptors with dif-
ferent chemical aﬃnities: muscarinic and nicotinic. This still did
not prove the concept of neurotransmission, although, in hind-
sight, it was an important step in its development.
Dale and the First World War
In 1914, Dale left his post at Wellcome to join the newly cre-
ated Medical Research Committee (later the National Institute
for Medical Research) where he became the Head of the Depart-
ment of Biochemistry and Pharmacology. Located in an old tu-
berculosis hospital at Mount Vernon, in Hampstead, north Lon-
don, MRC was an organisation with large funds provided by the
British government for medical research. However, Dale’s work
on acetylcholine would be put on hold due to the outbreak of
the First World War. With his research priorities now directed to
wartime concerns, Dale began examining traumatic or secondary
wound shock, which could prove fatal among battle casualties.
Dale knew this was in large part due to the body’s release of his-
tamine which greatly diminished the ﬂow of blood to the left side
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Figure 2. Chemical synap-
tic transmission. Source:
Wikimedia Commons (cre-
ated by the user Looie496,
US National Institutes of
Health, National Institute on
Aging.
of the heart, and he found an eﬀective remedy using plasma trans-
fusion to increase the circulating blood volume. Dale also began
to undertake tests on drugs produced by the British and French
manufacturers to replace the German pharmaceuticals, including
Salvarsan for the treatment of syphilis, which had become a se-
rious problem amongst British soldiers. However, Dale soon re-
alised that this task was problematic since the medical substances
he was given to test often had diﬀerent potencies and safety lim-
its. Consequently, he began to promote and insist on more strin-
gent regulation. Many of his recommendations for improvements
in drug standardisation would later become commonplace and
adopted internationally.
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Experimental Proof for Chemical Neurotransmission
Although the possibility of chemical neurotransmission at the synapse
had ﬁrst been raised in the late nineteenth century, and the con-
cept of chemical receptors given credence in 1905 by Cambridge
physiologist Thomas Elliot, both ideas were contentious. For
many, it was much more likely that synaptic communication was
electrical than chemical. Indeed, Dale, for one, was not pre-
pared to speculate on the possibility of chemical neurotransmit-
ters when the evidence remained so highly tentative. The impasse
required a deﬁnitive demonstration of chemical neurotransmis-
sion, and this would be provided by Dale’s friend Otto Loewi
in 1920. A German of Jewish extraction, Loewi undertook an
experiment which has become part of pharmacological folklore.
Claiming to have woken from a dream on the night of EasterOn Easter Sunday, 1920,
Otto Loewi performed
what is arguably the
most famous experiment
in pharmacology.
Sat-
urday, 1920, where an idea for an experiment had come to him,
Loewi scribbled down his thoughts, only to ﬁnd he was unable to
decipher them in the next morning. The following night, Loewi
experienced the same dream, and this time took no chances. He
cycled to his laboratory and performed the experiment which took
less than two hours. Upon seeing the results the next morning,
Loewi’s research assistant is reputed to have said that it would
win him the Nobel Prize. It was an assessment that proved true.
The experiment was simple. Loewi placed the heart of a frog still
attached to its parasympathetic (vagus) and sympathetic nerves
in a saline chamber. He then stimulated the vagus nerve, which
he knew would cause the heartbeat to slow down. It was at this
point that Loewi did something new: He removed some of the
solution from the chamber and applied it to another heart whose
vagus nerve had been removed (deaﬀerented). The result was that
the beat of the deaﬀerented heart also began to slow. In fact, this
solution inhibited the heart as potently as vagal stimulation itself.
The only feasible explanation was that the ﬁrst heart had secreted
a chemical (or what Loewi called a neurohumoral substance) into
the saline, which then acted on the second heart. To conﬁrm this,
Loewi stimulated the sympathetic branch of the ﬁrst heart causing
it to beat faster. Again, he extracted the bathing ﬂuid and applied
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it to the second heart. This time, the heartbeat increased. Loewi
called the inhibiting agent from the vagus nerve ‘vagusstoﬀ ’, and
the accelerating agent ‘acceleransstoﬀ ’.
In the years after his experiment, Loewi attempted to identify the
chemical nature of these two substances. Although Loewi sus-
pected that the inhibitory agent was acetylcholine and the ex-
citatory agent an adrenaline-like substance, it would take many
more experiments before the answers became clear. Nonetheless,
Loewi would be proven correct with acetylcholine being identi-
ﬁed as the vagal depressor substance, a theory he helped to prove
by ﬁnding small traces of cholinesterase in the heart tissue in
1930. Later, noradrenaline would be recognised as the acceler-
ator substance – the same neurochemical that Dale had shown
earlier to mimic the eﬀects of sympathetic stimulation.
Conﬁrming Acetylcholine as a Neurotransmitter
By the late 1920s, evidence In 1929, Dale along with
Harold Dudley managed
to extract one-third of a
gram of acetylcholine
from seventy-one
pounds of horse spleen.
had accumulated to convince many
that acetylcholine was a neurotransmitter – at least in the auto-
nomic nervous system. However, before acetylcholine could be
fully established as having this role, it would have to be identi-
ﬁed as a natural chemical in the body. This was no easy task. If
acetylcholine was being released from the nerve endings, then the
amounts were minuscule and most probably broken down almost
immediately. In fact, Dale was confronting similar diﬃculties
with histamine. But the doubts over histamine were dispelled in
1927 when Dale and chemist Harold Dudley managed to isolate
it from the liver and lungs. During this work, Dale had also tested
extracts of horse spleen which indicated that it might contain
acetylcholine. Although Dale had no idea why the spleen might
store acetylcholine, he set about visiting a local slaughterhouse
to collect tissue from freshly killed horses and oxen. From this
endeavour in 1929, Dale and Dudley managed to obtain seventy-
one pounds of tissue, from which they extracted one-third of a
gram of acetylcholine. It was a tiny amount, but enough to prove
that acetylcholine was a natural constituent of biological tissue.
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By the early 1930s, most pharmacologists accepted that the parasym-
pathetic branch of the vagus nerve secreted acetylcholine. But,
there was little evidence to show that it acted in a similar fashion
elsewhere. This situation changed in 1933 when Dale managed
to employ Wilhelm Feldberg, who had been forced to leave his
university post in Berlin when the Nazi party came to power. In
Germany, Feldberg had developed a highly eﬀective way of mea-
suring acetylcholine, which involved recording the contractions
of a leech muscle that had been pre-treated with the drug eser-
ine (also known as physostigmine). Remarkably, this increased
the muscle’s sensitivity to acetylcholine more than a million-fold.
And, it was a technique sensitive enough to detect the presence
of acetylcholine extracted from the ﬂuids of animals such as cats
and dogs.
FeldbergIn 1936, Henry Dale,
along with friend Otto
Loewi, shared the Nobel
Prize “for their
discoveries relating to
the chemical
transmission of nerve
impulses”.
set about doing this by stimulating a given nerve and
then collecting the blood drawn from a nearby vein, hoping that it
would reveal tiny amounts of acetylcholine when it was then ap-
plied to a leech muscle. In fact, this technique proved so success-
ful over the next three years that Feldberg established the sites
of acetylcholine release throughout the peripheral nervous sys-
tem, producing a spate of some twenty-four papers in the Jour-
nal of Physiology. He showed that acetylcholine was secreted at
many more places in the nervous system than previously envis-
aged, including the nerve endings of the parasympathetic nervous
system and the synapse at the preganglionic and postganglionic
junctions of the sympathetic system. Adding to all these new dis-
coveries, acetylcholine was found to be the neurotransmitter at
the neuromuscular junctions where it controlled voluntary mus-
cles. In 1936, Dale and Loewi shared the Nobel Prize “for their
discoveries relating to chemical transmission of nerve impulses”.
Their work has been described by one of the commentators as
“the greatest advance in neuroscience of the twentieth century”.
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Figure 3. The Nobel Prize
certiﬁcate awarded to Henry
Dale in 1936. Source: Well-
come Library, London.
The Soup Versus Sparks Debate
In his 1936 Nobel Prize acceptance speech, Dale had speculated
on the possibility of identifying chemical neurotransmitters in the
brain and spinal cord (CNS). However, proving that these sub-
stances existed and acted in the peripheral nervous systems had
been diﬃcult enough. Conﬁrming chemical neurotransmission in
the CNS would be a much more formidable challenge. The prob-
lem was not so much as to identifying potential neurotransmitter
substances, but also proving that they did not serve some other
physiological roles.
An outspoken critic of chemical neurotransmission in the CNS
at the time (he favoured electrical transmission instead) was the
Australian John Eccles - a renowned neurophysiologist who had
been a doctoral student under Charles Sherrington at Oxford af-
ter winning a Rhodes scholarship. He had then returned to Aus-
tralia where he examined the electrophysiological properties of
the neuromuscular junction. Later, after moving to the University
of Otago, New Zealand, he undertook the ﬁrst ever intracellu-
lar recordings of nerve cells in the CNS in 1950. This advance
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was made possible by the development of extremely ﬁne glass
micropipette electrodes which had a tip diameter of about 0.5
microns (about ﬁfty-thousandths of an inch). Armed with this
new technique, Eccles began examining the responses of motor
neurons passing out to the quadriceps muscle of the thigh from
the spinal cord in anaesthetised cats. When Eccles stimulated a
known feedback pathway to these motor neurons, that arose from
sensory muscle spindles, with a small electrical current, he found
that it caused the resting potential (voltage) inside the cell to tem-
porarily increase slightly.
This appeared to conﬁrm his theory of electrical neurotransmis-
sion. A year later, Eccles used a similar procedure to stimulate the
sensory pathway originating from the hamstrings of the posterior
thigh – that is, the opposing muscle to the quadriceps. This time,
however, he obtained an inhibitory postsynaptic potential (IPSP)
in the quadriceps motor neuron. In other words, the cell now be-
came more negative for a brief period, making it more resistant to
ﬁring. The only reasonable explanation was that both excitatory
and inhibitory chemical synapses had to exist. Thus, Eccles was
forced to admit that the concept of chemical neurotransmission
was correct after all. Later, Dale would write that “a remarkable
conversion” had occurred to Eccles, which was similar to “Saul
on his way to Damascus when sudden light shone and the scales
fell from his eyes”. Eccles, who was a devout theist, would prob-
ably not have minded the simile.
Dale in Later Life
Dale remained at the National Institute for Medical Research,
where he had become Director), until his retirement in 1942,
although he would continue serving on many government com-
mittees and play a leading role in numerous learned and medical
societies well into old age. Highlights of his numerous awards
include a knighthood in 1932, the Royal Society’s Copley Medal
in 1937, and the Knight’s Grand Cross Order of the British Em-
pire in 1948 – an award normally reserved for royalty and heads
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of state. A man who was said to be aﬀable, genial, unstinting in
his support of colleagues, Dale was regarded in enormous aﬀec-
tion by all who knew him. As President of the Royal Society, a
post he held from 1940 to 1945, he espoused the cause of women
in science and spoke publicly on a wide range of issues including
the need for the scientiﬁc establishment to adopt a “new responsi-
bility for the future of mankind”. Dale also continued as a trustee
for the Wellcome Trust overseeing grant awards for research until
his 85th birthday in 1960. Even then, he only cut back his work
a little, remaining as a scientiﬁc advisor until one week before he
died in a Cambridge nursing home at the age of 93 years in 1968.
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